William Blair Reiterates “Outperform” Rating for Exact Sciences (NASDAQ:EXAS)

Exact Sciences is a medical diagnostics company that specializes in liquid biopsies for cancer detection. The company's flagship product is CAPRA TT, a liquid biopsy test that detects cancer cells in blood samples.

William Blair is an investment firm that provides financial advisory services to companies and investors. In its research note on Exact Sciences, William Blair reiterated its "outperform" rating for the company's NASDAQEXAS stock. This means that William Blair believes that Exact Sciences' stock will outperform the broader market in the future.

In addition to restating its rating, William Blair also issued estimates for Exact Sciences' Q2 2025 earnings at $0.04 EPS (earnings per share), Q3 2025 earnings at $0.04 EPS, and Q4 2025 earnings at $0.13 EPS. These estimates are based on the company's financial performance in recent quarters and its growth prospects.

It is important to note that these estimates are subject to change based on a variety of factors, including changes in the competitive landscape, regulatory developments, and economic conditions. Investors should carefully consider these risks when making investment decisions.